Antimicrobial agents for myocarditis: Target the pathway, not the pathogen

Heart

Volumn 96, Issue 7, 2010, Pages 494-495

  Blauwet, Lorie A ^a   Cooper Jr , Leslie T ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; BETA INTERFERON; CEFTRIAXONE; CLARITHROMYCIN; DOXYCYCLINE; ERYTHROMYCIN; FUROSEMIDE; LOSARTAN; MACROLIDE; PLECONARIL;

CHLAMYDOPHILA PNEUMONIAE; CONGESTIVE CARDIOMYOPATHY; COXIELLA BURNETII; EDITORIAL; HEART FAILURE; MYCOPLASMA PNEUMONIAE; MYOCARDITIS; PRIORITY JOURNAL; VIRUS MYOCARDITIS;

ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; CLARITHROMYCIN; HUMANS; MYOCARDITIS;

EID: 77950582998     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/hrt.2009.173740     Document Type: Editorial

References (15)

1. Fournier PE, Etienne J, Harle JR, et al. Myocarditis, a rare but severe manifestation of Q fever: report of 8 cases and review of the literature. Clin Infect Dis 2001;32:1440-7.
2. Vogiatzis I, Dimoglou G, Sachpekidis V. Q Fever myocarditis. Hippokratia 2008;12:46-9.
3. Murcia J, Reus S, Climent V, et al. [Acute myocardial failure in a young man: Q-fever myocarditis] (In Spanish.). Rev Esp Cardiol 2002;55:875-7.
4. Hoefer D, Poelzl G, Kilo J, et al. Early detection and successful therapy of fulminant Chlamydia pneumoniae myocarditis. ASAIO J 2005;51:480-1.
5. Walder G, Gritsch W, Wiedermann CJ, et al. Co-infection with two Chlamydophila species in a case of fulminant myocarditis [see comment]. Crit Care Med 2007;35:623-6.
6. Paz A, Potasman I. Mycoplasma-associated carditis. Case reports and review. Cardiology 2002;97:83-8.
7. Tang Q, Huang J, Qian H, et al. Microarray analysis reveals the role of matrix metalloproteinases in mouse experimental autoimmune myocarditis induced by cardiac myosin peptides. Cell Mol Biol Lett 2007;12:176-91.
8. Pauschinger M, Chandrasekharan K, Schultheiss HP. Myocardial remodeling in viral heart disease: possible interactions between inflammatory mediators and MMP-TIMP system. Heart Fail Rev 2004;9:21-31.
9. Liu W, Feng W, Wang F, et al. Osteoprotegerin/RANK/RANKL axis in cardiac remodeling due to immuno-inflammatory myocardial disease. Exp Mol Pathol 2008;84:213-7.
10. Pauschinger M, Rutschow S, Chandrasekharan K, et al. Carvedilol improves left ventricular function in murine coxsackievirus-induced acute myocarditis association with reduced myocardial interleukin-1beta and MMP-8 expression and a modulated immune response. Eur J Heart Fail 2005;7:444-52.
11. Crocker SJ, Frausto RF, Whitmire JK, et al. Amelioration of coxsackievirus B3-mediated myocarditis by inhibition of tissue inhibitors of matrix metalloproteinase-1. Am J Pathol 2007;171:1762-73.
12. Cheung C, Luo H, Yanagawa B, et al. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in coxsackievirus-induced myocarditis. Cardiovasc Pathol 2006;15:63-74.
13. Cheung C, Marchant D, Walker EK, et al. Ablation of matrix metalloproteinase-9 increases severity of viral myocarditis in mice. Circulation 2008;117:1574-82.
14. Matsusaka H, Ikeuchi M, Matsushima S, et al. Selective disruption of MMP-2 gene exacerbates myocardial inflammation and dysfunction in mice with cytokine-induced cardiomyopathy. Am J Physiol Heart Circ Physiol 2005;289:H1858-64.
15. Hishikari K, Watanabe R, Ogawa M, et al. Early treatment with clarithromycin attenuates rat autoimmune myocarditis via inhibition of matrix metalloproteinase activity. Heart 2010;96:523-6.